The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.
July 25th 2024
The sNDA for furosemide seeks to expand the indication to include the treatment of edema due to fluid overload in patients with CKD, with a PDUFA date of March 6, 2025.
Expert Illustrations & Commentaries™: Exploring the Role of Novel Agents for the Management of IgA Nephropathy
View More
‘REEL’ Time Patient Counseling™: Navigating the Complex Journey of Diagnosing and Managing Fabry Disease
View More
Patient, Provider & Caregiver Connection™: Implementing an Effective Management Plan to Improve Outcomes in IgA Nephropathy
View More
Phase 2 Bardoxolone Trial Shows Efficacy for Alport Syndrome- & ADPKD-Caused CKD
Positive data collected from 2 phase 2 trials evaluating bardoxolone methyl in patients with chronic kidney disease (CKD) caused by Alport syndrome and autosomal dominant polycystic kidney disease (ADPKD) have been reported.
End-Stage Renal Disease Elevates Risk of Macular Degeneration
Age-related macular degeneration (AMD) was 72% more likely to develop in end-stage renal disease patients than in control subjects and 74% more likely to develop in peritoneal dialysis patients than in hemodialysis patients.
People with Advanced Chronic Kidney Disease Need More Vitamin D
April 1st 2016Vitamin D has shown to play an important role in those with multiple sclerosis, chronic obstructive pulmonary disease (COPD), and even depression; now it looks like the same can be said about those with stage 3 or 4 chronic kidney disease (CKD).
There is no shortage of people in need of a kidney transplant but a considerable shortage in the number of organs available to these patients. Despite that health care professionals in nephrology are determined to provide their patients the highest quality of life possible in spite of these challenges.
Medical Ethics: Should Older Patients with Heart and Kidney Failure Be Left to Die?
Older patients with heart and kidney failure can be helped with cardiac resynchronization therapy, a new study finds. But implanting devices to treat them is expensive, invasive, and not a full cure for many patients. Maybe it's better to ask these patients if they wouldn't rather die, two physicians argue.
Finerenone vs. Eplerenone: Trial Shows Mixed Results
In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide. But it had other benefits.
NAFLD Is Associated with Increased Risk for a Range of Severe Comorbidities
May 27th 2015Besides being the most common cause of chronic liver disease in industrialized nations, non-alcoholic fatty liver disease has serious hepatic consequences. It is expected to be the most frequent indication for liver transplantation by 2030.
Antithrombotic Therapy in Patients with Atrial Fibrillation and Chronic Kidney Disease
May 14th 2015The presence of chronic kidney disease (CKD) in patients with atrial fibrillation increases the risk of stroke and thromboembolism (TE) as well as the risk of bleeding, thus complicating their treatment. In this context, it has been suggested that CKD should be included in the CHA2DS2-VASc (Congestive heart failure; Hypertension; Age ≥75 years; Diabetes mellitus; previous Stroke, transient ischemic attack, or thromboembolism; Vascular disease; Age 65 to 74 years; Sex category) score.
Chronic Kidney Disease: Sleep Problems Increases with Disease Progression
April 13th 2015Lack of sleep and chronic kidney disease (CKD) independently lead to hypertension, diabetes mellitus, lower quality of life, and shorter life expectancy. Severity of CKD and sleep disturbances may also worsen diabetes and hypertension synergistically.
The US Food and Drug Administration (FDA) issued a strong warning on a drug used to treat iron deficiency anemia in patients with chronic kidney disease. Intravenous injections of ferumoxytol (Feraheme/Amag Pharmaceuticals) can cause serious allergic reactions including death in patients who are sensitive to the drug, the FDA cautioned in a new boxed warning. The drug was approved in 2009.
Kidney Disease Risk Higher with Longer Exposure to Antiretrovirals, Study Finds
March 1st 2015Chronic kidney disease developed in association with exposure to antiretrovirals in people with initially normal levels of estimated glomerular filtration rate (eGFR) was not limited to increased incidence immediately after starting therapy but in fact increased over time and exposure.